據報2021年國家醫保談判將於明日開始 爲期三日
據內地媒體從相關參與方獲悉,2021年國家醫保談判將於明日(9日)開始,週四(11日)結束,爲期三天。備受關注的PD-1單抗談判將在週三(10日)進行。
《經濟參考報》報道,2021年國家醫保藥品目錄調整步入談判階段,醫保目錄現場談判即將展開。據多家券商研究機構梳理,今年預計約有20個國產創新藥品種進行初次談判,包括PARP抑制劑、BTK抑制劑、ALK抑制劑、ADC藥物(抗體偶連藥物)、CAR-T療法(嵌合抗原受體T細胞免疫療法)等,涉及貝達藥業(300558.SZ)、百濟神州(06160.HK)、恆瑞醫藥(600276.SH)、澤璟製藥(688266.SH)等多家上市藥企。(ta/) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.